Search

Displaying results 6411 - 6420 of 10000 in total
  1. Drug

    Acetohydroxamic acid

    go.drugbank.com/drugs/DB00551
    ApprovedInvestigational

    Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease.

    Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylamineProducts: QUINOPRON ® INYECTABLE 200 MG, CIPROFLOXACINO 100 MG/10 ML INYECTABLE
  2. Target

    cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A

    go.drugbank.com/bio_entities/BE0000631
    TargetHumans

    Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides (PubMed:10373451, PubMed:10393245, PubMed:16330539, PubMed:17389385, PubMed:27058447). Can hydrolyze both cAMP and cGMP, but has high...

    Polypeptides: cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AFunction: 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
  3. Target

    2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2

    go.drugbank.com/bio_entities/BE0002203
    TargetHumans

    Polypeptides: 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2
  4. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. … [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and

    Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MG, Corzide Tab W Nadolol 80mgCategories: MATE 2 Substrates, MATE 1 Substrates
  5. Drug

    Iopamidol

    go.drugbank.com/drugs/DB08947
    ApprovedInvestigational

    Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

    Categories: X-Ray Contrast Activity, X-Ray Contrast Media, IodinatedProducts: PAMIRAY 370 ENJ. 50 ML 0,755 MG FLAKON, 1 ADET, Jopamiro 300 mg J/ml - Stechampullen
  6. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved

    Products: STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET
  7. Drug

    Mosapride

    go.drugbank.com/drugs/DB11675
    Investigational

    Mosapride is under investigation for the treatment and prevention of Postoperative Ileus and Gastric Peroral Endoscopic Pyloromyotomy (G-POEM). … Mosapride has been investigated for the treatment and diagnostic of Constipation, Type 2 Diabetes, Functional Dyspepsia, Functional Constipation, and Epigastric Pain Syndrome, among others.

    Mixtures: GASPRID-S, BONDIGEST COMPLEX® TABLETASCategories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. … This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.

    Categories: Interleukin-1 Receptor AntagonistSynonyms: Interleukin-1 receptor antagonist anakinra
  9. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    Eculizumab is a monoclonal antibody that targets complement protein C5. … [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.

    Categories: Complement C5 inhibitorsProducts: Bekemv 300 mg/30 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET, ELİZARİA 300 MG/30 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET
  10. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®

    Products: XGEVA® 120 MG/1.7 ML, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET